Pouria Akhbari

Dr. Pouria Akhbari

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
PAPaola S. Apaolaza
Paola S. Apaolaza
DBDiana Balcacean
Diana Balcacean
JZJose Zapardiel-Gonzalo
Jose Zapardiel-Gonzalo
GNGrace Nelson
Grace Nelson
NLNataliya Lenchik
Nataliya Lenchik
NGnPOD-Virus Group
nPOD-Virus Group
Interferon response sensors are expressed in the islet of Langerhans during the course of type 1 diabetes.

14 November 2025 in Science Advances
Verified
Journal Article
Open access
KMKathryn Murrall
Kathryn Murrall
TLTeifion Luckett
Teifion Luckett
CLChristiana Lekka
Christiana Lekka
CFChristine S. Flaxman
Christine S. Flaxman
RWRebecca Wyatt
Rebecca Wyatt
SRSarah Richardson
Sarah Richardson
Recent three-dimensional (3D) analyses reported an abundance of small β cell–rich endocrine objects (EOs) in the human pancreas. Here, we used archival, immunolabeled 2D pancreas sections to assess morphological EO parameters in donors with or without type 1 diabetes (T1D), varying in age and disease duration. We confirm that abundant small, insulin-positive EOs are present in donors without diabetes and comprise most of the pancreatic endocrine area in early life. Small EOs are virtually absent in individuals with T1D, and this effect is most pronounced in children diagnosed with T1D in their earliest years. We conclude that extraislet β cells are affected in T1D development, and their early loss is a characteristic feature. This finding has important implications, which will inform future screening and treatment strategies for T1D.

15 September 2020 in Microorganisms
Verified
Journal Article
Open access
PDF file
PAPouria Akhbari
Pouria Akhbari
SRSarah Richardson
Sarah Richardson
NMNoel Morgan
Noel Morgan
Enteroviruses (EVs) have long been implicated in the pathogenesis of type 1 diabetes (T1D), and accumulating evidence has associated virus-induced autoimmunity with the loss of pancreatic beta cells in T1D. Inflammatory cytokines including interferons (IFN) form a primary line of defence against viral infections, and their chronic elevation is a hallmark feature of many autoimmune diseases. IFNs play a key role in activating and regulating innate and adaptive immune responses, and to do so they modulate the expression of networks of genes and transcription factors known generically as IFN stimulated genes (ISGs). ISGs in turn modulate critical cellular processes ranging from cellular metabolism and growth regulation to endoplasmic reticulum (ER) stress and apoptosis. More recent studies have revealed that IFNs also modulate gene expression at an epigenetic as well as post-transcriptional and post-translational levels. As such, IFNs form a key link connecting the various genetic, environmental and immunological factors involved in the initiation and progression of T1D. Therefore, gaining an improved understanding of the mechanisms by which IFNs modulate beta cell function and survival is crucial in explaining the pathogenesis of virally-induced T1D. This should provide the means to prevent, decelerate or even reverse beta cell impairment.

17 March 2025 in Diabetologia
Verified
Journal Article
Open access
PDF file
TRTeresa Rodriguez-Calvo
Teresa Rodriguez-Calvo
JLJutta Laiho
Jutta Laiho
MOMaarit Oikarinen
Maarit Oikarinen
PAPouria Akhbari
Pouria Akhbari
CFChristine Flaxman
Christine Flaxman
FGfor the nPOD-Virus group
for the nPOD-Virus group
Aims/hypothesis: Earlier studies of pancreases from donors with type 1 diabetes demonstrated enteroviral capsid protein VP1 in beta cells. In the context of a multidisciplinary approach undertaken by the nPOD-Virus group, we assessed VP1 positivity in pancreas and other tissues (spleen, duodenum and pancreatic lymph nodes) from 188 organ donors, including donors with type 1 diabetes and donors expressing autoantibody risk markers. We also investigated whether VP1 positivity is linked to the hyperexpression of HLA class I (HLA-I) molecules in islet cells. Methods: Organ donor tissues were collected by the Network for Pancreatic Organ Donors with Diabetes (nPOD) from donors without diabetes (ND, n=76), donors expressing a single or multiple diabetes-associated autoantibodies (AAb+, n=20; AAb++, n=9) and donors with type 1 diabetes with residual insulin-containing islets (T1D-ICIs, n=41) or only insulin-deficient islets (T1D-IDIs, n=42). VP1 was assessed using immunohistochemistry (IHC) and HLA-I using IHC and immunofluorescence, in two independent laboratories. We determined assay concordance across laboratories and overall occurrence of positive assays, on a case-by-case basis and between donor groups. Results: Islet cell VP1 positivity was detected in most T1D-ICI donors (77.5%) vs only 38.2% of ND donors (p<0.001). VP1 positivity was associated with HLA-I hyperexpression. Of those donors assessed for HLA-I and VP1, 73.7% had both VP1 immunopositivity and HLA-I hyperexpression (p<0.001 vs ND). Moreover, VP1+ cells were detected at higher frequency in donors with HLA-I hyperexpression (p<0.001 vs normal HLA-I). Among VP1+ donors, the proportion with HLA-I hyperexpression was significantly higher in the AAb++ and T1D-ICI groups (94.9%, p<0.001 vs ND); this was not restricted to individuals with recent-onset diabetes. Critically, for all donor groups combined, HLA-I hyperexpression occurred more frequently in VP1+ compared with VP1− donors (45.8% vs 16%, p<0.001). Conclusions/interpretation: We report the most extensive analysis to date of VP1 and HLA-I in pancreases from donors with preclinical and diagnosed type 1 diabetes. We find an association of VP1 with residual beta cells after diagnosis and demonstrate VP1 positivity during the autoantibody-positive preclinical stage. For the first time, we show that VP1 positivity and HLA-I hyperexpression in islet cells are both present during the preclinical stage. While the study of tissues does not allow us to demonstrate causality, our data support the hypothesis that enterovirus infections may occur throughout the natural history of type 1 diabetes and may be one of multiple mechanisms driving islet cell HLA-I hyperexpression. Graphical

17 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KMKathryn Murrall
Kathryn Murrall
TLTeifion Luckett
Teifion Luckett
CLChristiana Lekka
Christiana Lekka
CFChristine S. Flaxman
Christine S. Flaxman
RWRebecca Wyatt
Rebecca Wyatt
SRSarah Richardson
Sarah Richardson
Recent 3D analyses reported abundant, small beta-cell-rich endocrine objects (EOs) in the human pancreas. Here, we assessed morphological parameters of >262,000 EOs in pancreas sections from 220 donors with or without type 1 diabetes (T1D), ranging in age and disease duration. We observe many insulin (Ins)+/glucagon (Gluc)-EOs in donors without diabetes. Their relative contribution to the total endocrine area is greatest in early life (0-2y) but reduces thereafter. Strikingly, we show the virtual absence of Ins+Gluc- EOs in individuals with T1D, where only the medium and large EOs retain beta cells. We also report a lower EO density in T1D, especially in individuals diagnosed in early life. These findings suggest that extra-islet beta cells are impacted in the development of T1D, and their early loss is a characteristic feature. This new understanding has important implications for defining beta-cell mass, which may inform future screening and treatment strategies in T1D. Highlights The present extensive 2D studies confirm and extend recent 3D analyses of human pancreata, demonstrating that 50% of endocrine objects (EOs) are much smaller than classical islets of Langerhans and consist predominantly of beta cells (Ins+). Small insulin+ EOs comprise the largest proportion of the total endocrine area in early childhood and persist throughout the life course in donors without diabetes. There is a shift towards larger EO size with increasing age, with the most pronounced changes in size occurring in the first few years of life. Small Ins+ EOs are virtually absent in individuals with type 1 diabetes, while the persisting EOs with beta cells are larger, suggesting a selective destruction of beta cells in small EOs. Development of type 1 diabetes, particularly at an early age, is associated with fewer larger EOs in adulthood. This implies that the lack or early destruction of small Ins+ EOs may be detrimental to the generation of larger EOs.

1 October 2014 in International Journal of Oncology
Verified
Journal Article
Closed access
PAPouria Akhbari
Pouria Akhbari
AWAdrian Whitehouse
Adrian Whitehouse
JBJames R. Boyne
James R. Boyne
NoMetastatic melanoma is the leading cause of skin‑cancer related deaths and while in recent years some progress has been made with targeted therapies, there remains an urgent unmet need for novel therapeutic treatments and reliable diagnostic, prognostic and predictive biomarkers. The emergence of next generation sequencing (NGS) has seen a growing appreciation for the role played by non‑coding genomic transcripts in regulating gene expression and by extension impacting on disease progression. The long non‑coding RNAs (lncRNAs) represent the most enigmatic of these new regulatory molecules. Our understanding of how lncRNAs regulate biological functions and their importance to disease aetiology, while still limited, is rapidly improving, in particular with regards to their role in cancer. Herein we review the identification of several lncRNAs shown to impact on melanoma disease progression and discuss how these molecules are operating at the molecular level